|
| Study ID | Clinical trials identifier | Year started | Immunogen/description | Country | Population enrolled | Note | References |
|
| IAVI B003 | NCT01215149 | 2010 | Adenovirus serotype 26 with an HIV-1 envelope A insert (Ad26.EnvA)
Adenovirus serotype 35 with an HIV-1 envelope A insert (Ad35.Env) | US, Kenya
Rwanda, South Africa | Healthy adults
of both sexes | Homologous and heterologous regimens | [150] |
|
| MENSCH | NCT02218125 | 2014 | MVA-vectored HIV-1 bivalent mosaic immunogen vaccine (MVA.mos1 and MVA.mos2; MVA Mosaic) which delivered two different but complementary HIV-1 gag/pol/env inserts | US, Kenya
Rwanda, South Africa | Healthy adults of both sexes and
those who had received two or three doses of NCT00618605 | — | [127] |
|
| APPROACH | NCT02315703 | 2014 | Prime: Ad26.Mos1.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol
Boost: Ad26.Mos.HIV or MVA-mosaic with or without gp140 protein | US, Rwanda,
South Africa, Thailand, Uganda | Healthy adults
of both sexes | Aluminum phosphate adjuvanted with clade C Env gp140 protein | [144] |
|
| CR108068 | NCT02685020 | 2016 | Ad26.Mos.HIV mosaic Env, Gag, and Pol antigens
Clade C gp140 | US | Healthy adults
of both sexes | — | [151] |
|
| TRAVERSE | NCT02788045 | 2016 | Prime: trivalent Ad26.Mos.HIV or tetravalent Ad26.Mos4.HIV
Boost: trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or Ad26.Mos4.HIV and Clade C gp140 plus adjuvant | US, Rwanda | Healthy adults
of both sexes | — | [152] |
|
| ASCENT | NCT02935686 | 2017 | Prime: tetravalent Ad26.Mos4.HIV
Boost: tetravalent Ad26.Mos4.HIV and Clade C gp140 plus adjuvant or a combination of Mosaic gp140 and Clade C gp140 plus adjuvant or HIV Bivalent Vaccine | US, Kenya, Rwanda | Healthy adults
of both sexes | Clinical trial not completed | — |
|
| IMBOKODO | NCT03060629 | 2017 | Prime: tetravalent Ad26.Mos4.HIV
Boost: Clade C gp140 with aluminum phosphate adjuvant | Malawi, Mozambique, South Africa, Zambia, Zimbabwe | Healthy, sexually active with male partners, at risk for HIV-1, adult females | The vaccine did not prevent HIV infection in high-risk women | [146] |
|
| IGHID 11810 | NCT03844386 | 2019 | Pilot study to evaluate the safety and immunogenicity of: MVA.tHIVconsv3 and MVA.tHIVconsv4, administered alone or in combination. Expression immunogens derived from conserved yet immunogenic regions of HIV-1 | US | HIV-1 infected adults
of both sexes under ART | Clinical trial completed, but no publications available | — |
|
| MOSAICO | NCT03964415 | 2020 | Prime: Ad26.Mos4.HIV is a tetravalent vaccine composed of Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1.Env, and Ad26.Mos2S.Env Clade C
Boost: Clade C and Mosaic gp140 HIV bivalent vaccine which contains: Clade C gp140, HIV-1 Env gp140 of Clade C, Mosaic gp140, HIV-1 Env gp140, and aluminum phosphate adjuvant | Uganda | Homosexual and bisexual men and trans women | Clinical trial stopped. According to the data, those who received the vaccine continued to contract HIV at a rate that was comparable to that of the other group | — |
|
| HIV-CORE 0052 | NCT04586673 | 2021 | Safety profile evaluation of: ChAdOx1.tHIVconv1, MVA.tHIVconsv3, and MVA.tHIVconsv4 | UK | Healthy adults
of both sexes | Clinical trial completed, but no publications available | — |
|
| HIV-CORE 006 | NCT04553016 | 2021 | Prime: ChAdOx1.tHIVconv1
Boost: MVA.tHIVconsv3 and MVA.tHIVconsv4 | Kenya, Uganda,
Zambia | Healthy adults of both sexes | Clinical trial completed, but no publications available | — |
|
